A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)

NCT07164833 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischemia Reperfusion Injury
Cardiac Surgery Associated - Acute Kidney Injury

Interventions

DRUG: BX-001N Experimental group 1
DRUG: BX-001N Experimental group 2
DRUG: Placebo

Sponsor

Bilix Co.,Ltd.